Elevated Serum Leucine Levels Are Associated With Cognitive Impairment and Reduced Gray Matter and Cerebral Volume Across the Alzheimer's Disease Continuum

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share this content! By

Elevated Serum Leucine Levels Are Associated With Cognitive Impairment and Reduced Gray Matter and Cerebral Volume Across the Alzheimer's Disease Continuum Publisher Pubmed

H Nasiri HAMIDE ; A Azargoonjahromi ALI ; Z Nouri ZAHRA ; Sm Azimi Sayed MEHRDAD ; H Zand HOSSEIN ; A Shourideh AMIR ; S Heydari SOUDABEH ; B Mahmoudvand BEHNAZ ; S Barabadi SOMAYEH ; N Samadpour NASTARAN

Source: Neuroscience Published:2025

Abstract

Leucine, a branched-chain amino acid (BCAA), exhibits paradoxical effects in Alzheimer's disease (AD), demonstrating both neuroprotective and neurotoxic roles. While prior studies have investigated leucine's systemic and metabolic impacts, its influence on brain structure remains unexplored. This study aimed to fill this critical gap by examining the relationship between serum leucine levels, brain volume metrics, and cognitive performance in individuals across the AD continuum. Serum leucine concentrations were quantified using the Nightingale Health nuclear magnetic resonance (NMR) platform. Cognitive performance was assessed using the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 11 and 13), and structural brain volumes, including total cerebrum, cerebrum gray matter, and total brain gray matter, were derived from T1-weighted magnetic resonance imaging (MRI) via automated segmentation. Mediation analysis was employed to determine whether changes in brain volume mediate the association between serum leucine levels and cognitive performance. Elevated serum leucine levels were significantly associated with reduced total cerebrum volume, cerebrum gray matter volume, and total brain gray matter volume. Furthermore, mediation analysis revealed that these reductions in brain volume partially mediated the relationship between higher leucine levels and poorer cognitive outcomes. These findings provide evidence linking elevated leucine levels to brain atrophy and cognitive decline in AD, suggesting a potentially deleterious role of leucine in neurodegeneration. This highlights the importance of further mechanistic investigations to clarify leucine's role in AD pathology and assess its viability as a therapeutic target. © 2025 Elsevier B.V., All rights reserved.

Related Docs

View other Related Docs

1. Evaluation and Estimation of Gray Matter Volume Using Voxel-Based Morphometry of the Brain Magnetic Resonance Imaging (Mri) in Normal Elderly People and Those With Mild Cognitive Impairment, Journal of Isfahan Medical School (2015)

2. Amino Acid Patterns Predict White Matter Integrity Measures in the Brain in Patients Across the Alzheimer’S Disease Continuum, Metabolic Brain Disease (2025)

3. Association of Metabolic Dysfunction With Cognitive Decline and Alzheimer's Disease: A Review of Metabolomic Evidence, Progress in Neuro-Psychopharmacology and Biological Psychiatry (2024)

Experts (# of related papers)

View all Related Experts

Majid Barekatain (2)

Saeed Kermani (2)

Other Related Docs

4. Use of Drugs Affecting Gabaa Receptors and the Risk of Developing Alzheimer’S Disease and Dementia: A Meta-Analysis and Literature Review, Molecular Neurobiology (2025)

5. Evaluating the Predictive Value of Oxylipins for Cognitive Measures And White Matter Hyperintensities in Alzheimer’S Disease Continuum Compared to Conventional Beta‑Amyloid and Tau Protein Biomarkers, Molecular Neurobiology (2025)

6. Diagnosis of Mild Cognitive Impairment (Mci) Via Estimating the Density of Gray Matter Using Voxel-Based Morphometry (Vbm) in the Brain Magnetic Resonance Imaging (Mri), Journal of Isfahan Medical School (2016)

7. A Comprehensive Investigation of the Associations Between Tensor-Based Morphometry Indices and Executive Functions, Memory, Language, and Visuospatial Abilities in Patients in the Alzheimer's Disease Continuum, Clinical Neurology and Neurosurgery (2024)

8. Associations Between Metabolomics Findings and Brain Hypometabolism in Mild Cognitive Impairment and Alzheimer’S Disease#, Current Alzheimer Research (2024)

9. Uncovering Cerebral Blood Flow Patterns Corresponding to Amyloid-Beta Accumulations in Patients Across the Alzheimer’S Disease Continuum Using the Arterial Spin Labeling, Neurological Sciences (2025)

10. Csf-Targeted Proteomics Indicate Amyloid-Beta Ratios in Patients With Alzheimer's Dementia Spectrum, International Journal of Alzheimer's Disease (2023)

11. Association of Brain and Ventricular Boundary Shift Integral Measurements With Csf Biomarkers: A Case-Control Study, Current Alzheimer Research (2025)

12. Growth-Associated Protein 43 Levels in the Cerebrospinal Fluid Correspond to the Cerebral Blood Flow Alterations in Alzheimer's Dementia Continuum: An Original Study, Health Science Reports (2025)

13. Effectiveness and Safety of Mlc601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial, Dementia and Geriatric Cognitive Disorders Extra (2015)

Style	Citing Format
MLA	H Nasiri HAMIDE, et al.. "Elevated Serum Leucine Levels Are Associated With Cognitive Impairment and Reduced Gray Matter and Cerebral Volume Across the Alzheimer's Disease Continuum." Neuroscience, vol. 577, no. , 2025, pp. 47-53.
APA	H Nasiri HAMIDE, A Azargoonjahromi ALI, Z Nouri ZAHRA, Sm Azimi Sayed MEHRDAD, H Zand HOSSEIN, A Shourideh AMIR, S Heydari SOUDABEH, B Mahmoudvand BEHNAZ, S Barabadi SOMAYEH, N Samadpour NASTARAN (2025). Elevated Serum Leucine Levels Are Associated With Cognitive Impairment and Reduced Gray Matter and Cerebral Volume Across the Alzheimer's Disease Continuum. Neuroscience, 577(), 47-53.
Chicago	H Nasiri HAMIDE, A Azargoonjahromi ALI, Z Nouri ZAHRA, Sm Azimi Sayed MEHRDAD, H Zand HOSSEIN, A Shourideh AMIR, S Heydari SOUDABEH, B Mahmoudvand BEHNAZ, S Barabadi SOMAYEH, N Samadpour NASTARAN. "Elevated Serum Leucine Levels Are Associated With Cognitive Impairment and Reduced Gray Matter and Cerebral Volume Across the Alzheimer's Disease Continuum." Neuroscience 577, no. (2025): 47-53.
Harvard	H Nasiri HAMIDE et al. (2025) 'Elevated Serum Leucine Levels Are Associated With Cognitive Impairment and Reduced Gray Matter and Cerebral Volume Across the Alzheimer's Disease Continuum', Neuroscience, 577(), pp. 47-53.
Vancouver	H Nasiri HAMIDE, A Azargoonjahromi ALI, Z Nouri ZAHRA, Sm Azimi Sayed MEHRDAD, H Zand HOSSEIN, A Shourideh AMIR, et al.. Elevated Serum Leucine Levels Are Associated With Cognitive Impairment and Reduced Gray Matter and Cerebral Volume Across the Alzheimer's Disease Continuum. Neuroscience. 2025;577():47-53.
BibTex	@article{ author = {H Nasiri HAMIDE and A Azargoonjahromi ALI and Z Nouri ZAHRA and Sm Azimi Sayed MEHRDAD and H Zand HOSSEIN and A Shourideh AMIR and S Heydari SOUDABEH and B Mahmoudvand BEHNAZ and S Barabadi SOMAYEH and N Samadpour NASTARAN}, title = {Elevated Serum Leucine Levels Are Associated With Cognitive Impairment and Reduced Gray Matter and Cerebral Volume Across the Alzheimer's Disease Continuum}, journal = {Neuroscience}, volume = {577}, number = {}, pages = {47-53}, year = {2025} }
RIS	TY - JOUR AU - H Nasiri HAMIDE AU - A Azargoonjahromi ALI AU - Z Nouri ZAHRA AU - Sm Azimi Sayed MEHRDAD AU - H Zand HOSSEIN AU - A Shourideh AMIR AU - S Heydari SOUDABEH AU - B Mahmoudvand BEHNAZ AU - S Barabadi SOMAYEH AU - N Samadpour NASTARAN TI - Elevated Serum Leucine Levels Are Associated With Cognitive Impairment and Reduced Gray Matter and Cerebral Volume Across the Alzheimer's Disease Continuum JO - Neuroscience VL - 577 IS - SP - 47 EP - 53 PY - 2025 ER -

Science Communicator Platform

Authors

Abstract